Intellia Therapeutics Investor Presentation — August 2018

Document content

Educational Briefing On

Interference Proceedings Relating To

CRISPR/Cas9 Genome Editing

Today’s Participants

•Cora Holt, Associate, Finnegan, Henderson, Farabow, Garrett & Dunner, LLP

•José Rivera, Executive Vice President and General Counsel, Intellia Therapeutics

•Lindsey Trickett, Vice President, Investor Relations, Intellia Therapeutics3

Intellia Therapeutics Legal Disclaimers

This presentation contains “forward -looking statements” ofIntellia Therapeutics, Inc.(“Intellia”) within themeaning

ofthePrivate Securities Litigation Reform Actof1995 .These forward -looking statements include, butarenot

limited to,express orimplied statements regarding thepatent interference proceedings between theUniversity of

California Berkeley andtheBroad Institute ;thescope oftheclaims covered bythepatent applications filed bythe

University ofCalifornia Berkeley andtheBroad Institute ;thedecision bytheU.S.Court ofAppeals fortheFederal

Circuit regarding thepatent interference proceedings between theUniversity ofCalifornia Berkeley andtheBroad

Institute andpotential next steps after adecision isrendered bytheU.S.Court ofAppeals fortheFederal Circuit ;

Intellia’s ability toadvance andexpand theCRISPR/Cas 9technology todevelop intohuman therapeutic products,

aswellasourCRISPR/Cas 9intellectual property portfolio ;ourability toachieve stable oreffective genome editing ;

andtheintellectual property position andstrategy ofIntellia’s licensors orother parties from which itderives rights .

Anyforward -looking statements inthispresentation arebased onmanagement’s current expectations andbeliefs

offuture events, and aresubject toanumber ofrisks and uncertainties that could cause actual results todiffer

materially and adversely from those setforth inorimplied bysuch forward -looking statements .These risks and

uncertainties include, butarenotlimited torisks related toIntellia’s ability toprotect and maintain ourintellectual

property position andrisks related totheability ofourlicensors toprotect andmaintain their intellectual property

position .Foradiscussion ofthese and other risks and uncertainties, and other important factors, anyofwhich

could cause Intellia’s actual results todiffer from those contained intheforward -looking statements, see the

section entitled “Risk Factors” inIntellia’s most recent annual report onForm 10-Kandquarterly reports onForm

10-Qfiled with theSecurities andExchange Commission, aswell asdiscussions ofpotential risks, uncertainties,

andother important factors inIntellia’s other filings with theSecurities andExchange Commission .Allinformation